Common Contracts
2 similar Product Sublicense Agreement contracts by Immune Pharmaceuticals Inc
EXECUTION VERSION DATED DECEMBER 7, 2010 iCo THERAPEUTICS INCORPORATED and IMMUNE PHARMACEUTICALS LTD. PRODUCT SUBLICENSE AGREEMENTProduct Sublicense Agreement • May 5th, 2020 • California
Portions of this Exhibit, indicated by the mark “[***]”, were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Exchange Act of 1934, as amended.
Standard Contracts
DATED DECEMBER 7, 2010 iCo THERAPEUTICS INCORPORATED and IMMUNE PHARMACEUTICALS LTD. PRODUCT SUBLICENSE AGREEMENTProduct Sublicense Agreement • October 3rd, 2014 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • California
This Product Sublicense Agreement is made and entered into on December 7, 2010 (the “Execution Date”) by and between iCo Therapeutics Incorporated, a corporation organized and existing under the laws of Canada with a place of business at Suite 760, 777 Hornby Street, Vancouver, BC, Canada, V6Z 1S4 (“iCo”), and Immune Pharmaceuticals Ltd.,, a corporation organized and existing under the laws of the State of Israel with a place of business for the purpose of this agreement at 1120 Avenue of the Americas, 7th Floor, New York, NY (“IMPH”). iCo and IMPH each may be referred to herein individually as a “Party” or, collectively, as the “Parties”.
